Laurion Capital Management’s Amicus Therapeutics FOLD Stock Holding History

Laurion Capital Management’s Portfolio FOLD Stock Details FOLD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-218,531	Closed	-$5.05M	–	800
2020 Q4	$5.05M	Buy	218,531 +200,831	+1,135%	+$4.11M	0.04%	246
2020 Q3	$250K	Buy	+17,700	New	+$258K	﹤0.01%	708
2020 Q1	–	Sell	-118,400	Closed	-$1.15M	–	870
2019 Q4	$1.15M	Buy	+118,400	New	+$1.08M	0.01%	544
2018 Q4	–	Sell	-37,627	Closed	-$455K	–	1202
2018 Q3	$455K	Buy	+37,627	New	+$526K	﹤0.01%	852
2017 Q1	–	Sell	-91,300	Closed	-$454K	–	1391
2016 Q4	$454K	Buy	+91,300	New	+$632K	﹤0.01%	857
2015 Q3	–	Sell	-284,906	Closed	-$4.03M	–	791
2015 Q2	$4.03M	Buy	+284,906	New	+$3.43M	0.04%	330

Other funds holding FOLD

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Laurion Capital Management's FOLD Position: Q1 2021 in Review

Laurion Capital Management sold out of Amicus Therapeutics (FOLD) in Q1 2021, closing a stake of 218,531 shares — an estimated $5.05M sold.

Laurion Capital Management first reported a position in FOLD in Q2 2015 and held it in 6 quarters. The position peaked at $5.05M in Q4 2020. 259 funds tracked by Wall St. Rank hold FOLD as of Q1 2021.

Laurion Capital Management reported no remaining Amicus Therapeutics position as of Q1 2021 after selling out during the quarter.
Laurion Capital Management sold 218,531 Amicus Therapeutics shares in Q1 2021, an estimated $5.05M.
Laurion Capital Management first reported a position in Amicus Therapeutics in Q2 2015 and held it in 6 quarters.
Laurion Capital Management's Amicus Therapeutics position peaked at $5.05M in Q4 2020.
259 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q1 2021.

Based on Laurion Capital Management's 13F filing for Q1 2021, filed 14 May 2021.